Abstract:Spatiotemporally controlled cargo release is a key advantage of nanocarriers in anti-tumor therapy. Various external or internal stimuli-responsive nanomedicines have been reported for their ability to increase drug levels at the diseased site and enhance therapeutic efficacy through a triggered release mechanism. Redox-manipulating nanocarriers, by exploiting the redox imbalances in tumor tissues, can achieve precise drug release, enhancing therapeutic efficacy while minimizing damage to healthy cells. As a typical redox-sensitive bond, the disulfide bond is considered a promising tool for designing tumor-specific, stimulus-responsive drug delivery systems (DDS). The intracellular redox imbalance caused by tumor microenvironment (TME) regulation has emerged as an appealing therapeutic target for cancer treatment. Sustained glutathione (GSH) depletion in the TME by redox-manipulating nanocarriers can exacerbate oxidative stress through the exchange of disulfide-thiol bonds, thereby enhancing the efficacy of ROS-based cancer therapy. Intriguingly, GSH depletion is simultaneously associated with glutathione peroxidase 4 (GPX4) inhibition and dihydrolipoamide S-acetyltransferase (DLAT) oligomerization, triggering mechanisms such as ferroptosis and cuproptosis, which increase the sensitivity of tumor cells. Hence, in this review, we present a comprehensive summary of the advances in disulfide based redox-manipulating nanocarriers for anticancer drug delivery and provide an overview of some representative achievements for combinational therapy and theragnostic. The high concentration of GSH in the TME enables the engineering of redox-responsive nanocarriers for GSH-triggered on-demand drug delivery, which relies on the thiol-disulfide exchange reaction between GSH and disulfide-containing vehicles. Conversely, redox-manipulating nanocarriers can deplete GSH, thereby enhancing the efficacy of ROS-based treatment nanoplatforms. In brief, we summarize the up-to-date developments of the redox-manipulating nanocarriers for cancer therapy based on DDS and provide viewpoints for the establishment of more stringent anti-tumor nanoplatform.

Nanomedicine-Enabled Chemical Regulation of Reactive X Species for Versatile Disease Treatments

Reactive X (where X = O, N, S, C, Cl, Br, and I) species nanomedicine

The progress of research on the application of redox nanomaterials in disease therapy

Nanomedicine-based Modulation of Redox Status for Cancer Therapy

Nanomaterial-based regulation of redox metabolism for enhancing cancer therapy

MXene‐Mediated Catalytic Redox Reactions for Biomedical Applications

Nanomaterials-Induced Redox Imbalance: Challenged and Opportunities for Nanomaterials in Cancer Therapy.

Redox regulation and its emerging roles in cancer treatment

Reactive Oxygen Species‐Regulating Strategies Based on Nanomaterials for Disease Treatment

Nanoparticles (Nps)-Mediated Targeted Regulation of Redox Homeostasis for Effective Cancer Therapy

Reactive Oxygen Species (ROS)-Based Nanomedicine.

Redox-responsive Theranostic Nanoplatforms Based on Inorganic Nanomaterials

Nanozymes Regulate Redox Homeostasis in ROS-Related Inflammation

Modulating Intracellular Oxidative Stress Via Engineered Nanotherapeutics

Nanotechnology Enabled Reactive Species Regulation in Biosystems for Boosting Cancer Immunotherapy

Redox control of the survival of healthy and diseased cells.

Oxidative‐Species‐Selective Materials for Diagnostic and Therapeutic Applications

Nanozymes for regulation of reactive oxygen species and disease therapy

Redox Signaling at the Crossroads of Human Health and Disease

Redox-manipulating nanocarriers for anticancer drug delivery: a systematic review

Recent Advances on Reactive Oxygen Species-Responsive Delivery and Diagnosis System